Condition: Prostate Cancer · Sponsor: Cambridge University Hospitals NHS Foundation Trust
This is a phase 2, randomised, multicentre, double-blind, placebo-controlled trial investigating the use of short term androgen deprivation therapy in the form of apalutamide (Erleada) in men on active surveillance for prostate cancer.
This description comes directly from the study's public registry record.
Elizabeth Young · 01223 256364 · cuh.taps02trial@nhs.net
Always discuss trial participation with your own doctor first.
| Addenbrooke's Hospital | Cambridge, Cambridgeshire, United Kingdom | Recruiting |
| Southmead Hospital | Bristol, United Kingdom | Recruiting |
| West Suffolk Hospital | Bury St Edmunds, United Kingdom | Recruiting |
| Darent Valley Hospital | Dartford, United Kingdom | Recruiting |
| St Bartholomew's Hospital | London, United Kingdom | Recruiting |
| The Royal Marsden Hospital - Chelsea | London, United Kingdom | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05191680